<!DOCTYPE html><html id="__next_error__"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-43e143f5559d1c90.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp"/><script src="/_next/static/chunks/fd9d1056-c176ba62bfa905c4.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp" async=""></script><script src="/_next/static/chunks/23-d290ffe682927bac.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp" async=""></script><script src="/_next/static/chunks/main-app-f73cdb3bce740b12.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp" async=""></script><meta name="robots" content="noindex"/><title>Teclison | Transforming cancer treatment by enhancing immunotherapy</title><meta name="description" content="At Teclison, we develop innovative cancer therapies to induce tumor necrosis and enhance antitumor immunity, offering patients with liver metastasis the hope of longer, better lives."/><meta name="keywords" content="Teclison,Cancer treatment,Immunotherapy"/><meta name="robots" content="noindex, follow, nocache"/><meta name="googlebot" content="index, nofollow, noimageindex, max-image-preview:large, max-snippet:-1"/><meta property="og:title" content="Teclison | Transforming cancer treatment by enhancing immunotherapy"/><meta property="og:description" content="Transforming cancer treatment by enhancing immunotherapy. At Teclison, we develop innovative cancer therapies to induce tumor necrosis and enhance antitumor immunity, offering patients with liver metastasis the hope of longer, better lives."/><meta property="og:url" content="https://www.teclison.com"/><meta property="og:site_name" content="Teclison"/><meta property="og:image" content="https://storage.googleapis.com/teclison/teclison_og_image.webp"/><meta property="og:type" content="website"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="Teclison | Transforming cancer treatment by enhancing immunotherapy"/><meta name="twitter:description" content="Transforming cancer treatment by enhancing immunotherapy. At Teclison, we develop innovative cancer therapies to induce tumor necrosis and enhance antitumor immunity, offering patients with liver metastasis the hope of longer, better lives."/><meta name="twitter:image" content="https://storage.googleapis.com/teclison/teclison_og_twitter.webp"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="64x64"/><meta name="next-size-adjust"/><script src="/_next/static/chunks/polyfills-78c92fac7aa8fdd8.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp" noModule=""></script></head><body><script src="/_next/static/chunks/webpack-43e143f5559d1c90.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0]);self.__next_f.push([2,null])</script><script>self.__next_f.push([1,"1:HL[\"/_next/static/media/3b401319a061ecfc-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:HL[\"/_next/static/css/1964e9c9e265d4cd.css?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"style\"]\n3:HL[\"/_next/static/css/469052ecc083fa88.css?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"style\"]\n"])</script><script>self.__next_f.push([1,"4:I[5751,[],\"\"]\nb:I[9275,[],\"\"]\nc:I[1343,[],\"\"]\nf:I[6130,[],\"\"]\n10:[]\n0:[null,[\"$\",\"$L4\",null,{\"buildId\":\"3VXyDvsAArbHQ68Dv-Xce\",\"assetPrefix\":\"\",\"initialCanonicalUrl\":\"/robots.txt\",\"initialTree\":[\"\",{\"children\":[[\"locale\",\"robots.txt\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]},\"$undefined\",\"$undefined\",true],\"initialSeedData\":[\"\",{\"children\":[[\"locale\",\"robots.txt\",\"d\"],{\"children\":[\"__PAGE__\",{},[[\"$L5\",[\"$\",\"main\",null,{\"className\":\"w-full overflow-x-hidden\",\"children\":[\"$L6\",\"$L7\",\"$L8\",\"$L9\"]}]],null],null]},[\"$La\",null],null]},[[\"$\",\"$Lb\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lc\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$Ld\",\"notFoundStyles\":[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1964e9c9e265d4cd.css?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]],\"styles\":[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1964e9c9e265d4cd.css?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]]}],null],null],\"couldBeIntercepted\":false,\"initialHead\":[false,\"$Le\"],\"globalErrorComponent\":\"$f\",\"missingSlots\":\"$W10\"}]]\n"])</script><script>self.__next_f.push([1,"12:I[8173,[\"739\",\"static/chunks/739-b88516ffa221270f.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"641\",\"static/chunks/641-e7a5c0801ce7e4bd.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"173\",\"static/chunks/173-89ea13df4be38b47.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"61\",\"static/chunks/app/%5Blocale%5D/page-6efb1ebf90caf47b.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\"],\"Image\"]\n6:[\"$\",\"section\",null,{\"className\":\"KeyVisual_background__fKOQv\",\"id\":\"home-kv\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex w-full max-w-[800px] flex-col justify-center p-5 md:w-1/2 md:p-7 lg:p-9 xl:p-14\",\"children\":[[\"$\",\"h1\",null,{\"className\":\"mb-5\",\"children\":\"Transforming cancer treatment by enhancing immunotherapy\"}],[\"$\",\"h3\",null,{\"className\":\"mb-14 text-blue text-sh4\",\"children\":\"We develop innovative cancer therapies to induce tumor necrosis and enhance antitumor immunity, offering cancer patients the hope of longer, better lives.\"}],\"$L11\"]}],[\"$\",\"div\",null,{\"className\":\"relative flex w-full items-end xs:ml-auto xs:mr-0 xs:w-1/2 lg:ml-0\",\"children\":[\"$\",\"$L12\",null,{\"alt\":\"Key Visual\",\"className\":\"h-auto w-full\",\"height\":1269,\"sizes\":\"100vw\",\"src\":\"/images/home/home_key_visual.png\",\"width\":1692}]}]]}]\n7:[\"$\",\"section\",null,{\"className\":\"flex flex-col md:flex-row\",\"id\":\"home-our-approach\",\"children\":[[\"$\",\"div\",null,{\"className\":\"relative w-full xs:w-1/2\",\"children\":[\"$\",\"$L12\",null,{\"alt\":\"Our Approach\",\"className\":\"h-auto w-[110%] max-w-[932px]\",\"height\":1398,\"sizes\":\"110vw\",\"src\":\"/images/home/home_our_approach.png\",\"width\":1295}]}],[\"$\",\"div\",null,{\"className\":\"flex w-full max-w-[800px] flex-col justify-center px-5 pb-[72px] pt-9 xs:p-5 md:w-1/2 lg:px-14 lg:py-6 xl:px-[76px] xl:py-8 2xl:px-24 2xl:py-10\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"mb-5\",\"children\":\"Our Approach\"}],[\"$\",\"h3\",null,{\"className\":\"mb-14 text-blue text-b1\",\"children\":\"Our innovative platform radically remodels the tumor immune microenvironment of solid cancers, unlocking the ability to successfully treat cancer patients who respond poorly to existing immunothe"])</script><script>self.__next_f.push([1,"rapies.\"}],\"$L13\"]}]]}]\n8:[\"$\",\"section\",null,{\"className\":\"OurPipelineSection_background__jQHvp\",\"id\":\"home-our-pipeline\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex w-full max-w-[800px] flex-col justify-center px-5 py-[72px] xs:p-5 md:w-[45%] md:p-10 lg:p-14 xl:p-16 2xl:p-20\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"mb-5\",\"children\":\"Our Pipeline\"}],[\"$\",\"h3\",null,{\"className\":\"mb-14 text-blue text-b1\",\"children\":\"Our innovative approaches aim to enhance immune checkpoint inhibitors (ICIs) and prolong the lives of patients with solid tumor cancers that have metastasized to the liver.\"}],\"$L14\"]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-center p-[30px] md:w-[55%] lg:items-end lg:p-0\",\"children\":[[\"$\",\"div\",null,{\"className\":\"h-[280px] w-[280px] items-center justify-center break-words rounded-full bg-white p-5 text-center text-blue text-b2 flex lg:hidden\",\"children\":\"\\\"We believe in our pipeline's ability to enhance and achieve long-term remission for patients\\\"\"}],[\"$\",\"$L12\",null,{\"alt\":\"Our Pipeline\",\"className\":\"hidden h-auto w-full lg:block\",\"height\":1578,\"sizes\":\"100vw\",\"src\":\"/images/home/home_our_pipeline.png\",\"width\":1091}]]}],[\"$\",\"div\",null,{\"className\":\"h-[280px] w-[280px] items-center justify-center break-words rounded-full bg-white p-5 text-center text-blue text-b2 absolute left-1/2 top-1/2 hidden -translate-x-1/2 -translate-y-1/4 lg:flex\",\"children\":\"\\\"We believe in our pipeline's ability to enhance and achieve long-term remission for patients\\\"\"}]]}]\n9:[\"$\",\"section\",null,{\"className\":\"flex flex-col md:flex-row\",\"id\":\"home-career\",\"children\":[[\"$\",\"div\",null,{\"className\":\"relative w-full xs:w-1/2\",\"children\":[\"$\",\"$L12\",null,{\"alt\":\"Careers and Contact Us\",\"className\":\"h-auto w-full max-w-[861px]\",\"height\":1335,\"sizes\":\"100vw\",\"src\":\"/images/home/home_career_contact_us.png\",\"width\":1292}]}],[\"$\",\"div\",null,{\"className\":\"flex max-w-[800px] flex-col justify-center gap-y-[70px] px-5 pb-[72px] pt-9 xs:gap-y-[140px] xs:p-5 md:w-1/2 lg:px-[60px] lg:pb-[154px] lg:pt-[100px] xl:px-[76px"])</script><script>self.__next_f.push([1,"] xl:pb-48 xl:pt-32 2xl:px-24 2xl:pb-[232px] 2xl:pt-[152px]\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h2\",null,{\"className\":\"mb-5\",\"children\":\"Careers\"}],[\"$\",\"h3\",null,{\"className\":\"mb-14 text-blue text-b1\",\"children\":\"Every day, we are exploring new ways to improve the lives of patients with solid tumor cancers. Join our growing team of experts.\"}],\"$L15\"]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h2\",null,{\"className\":\"mb-5\",\"children\":\"Contact Us\"}],[\"$\",\"h3\",null,{\"className\":\"mb-14 text-blue text-b1\",\"children\":\"For questions regarding partnership opportunities, investor relations, media coverage, or other inquiries, please reach out to us.\"}],\"$L16\"]}]]}]]}]\nd:[\"$\",\"html\",null,{\"lang\":\"en-US\",\"children\":[\"$\",\"body\",null,{\"className\":\"__className_0141c2\",\"children\":\"$L17\"}]}]\n"])</script><script>self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}],[\"$\",\"meta\",\"1\",{\"charSet\":\"utf-8\"}],[\"$\",\"title\",\"2\",{\"children\":\"Teclison | Transforming cancer treatment by enhancing immunotherapy\"}],[\"$\",\"meta\",\"3\",{\"name\":\"description\",\"content\":\"At Teclison, we develop innovative cancer therapies to induce tumor necrosis and enhance antitumor immunity, offering patients with liver metastasis the hope of longer, better lives.\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"Teclison,Cancer treatment,Immunotherapy\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"noindex, follow, nocache\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, nofollow, noimageindex, max-image-preview:large, max-snippet:-1\"}],[\"$\",\"meta\",\"7\",{\"property\":\"og:title\",\"content\":\"Teclison | Transforming cancer treatment by enhancing immunotherapy\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:description\",\"content\":\"Transforming cancer treatment by enhancing immunotherapy. At Teclison, we develop innovative cancer therapies to induce tumor necrosis and enhance antitumor immunity, offering patients with liver metastasis the hope of longer, better lives.\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:url\",\"content\":\"https://www.teclison.com\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:site_name\",\"content\":\"Teclison\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:image\",\"content\":\"https://storage.googleapis.com/teclison/teclison_og_image.webp\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",\"13\",{\"name\":\"twitter:card\",\"content\":\"summary_large_image\"}],[\"$\",\"meta\",\"14\",{\"name\":\"twitter:title\",\"content\":\"Teclison | Transforming cancer treatment by enhancing immunotherapy\"}],[\"$\",\"meta\",\"15\",{\"name\":\"twitter:description\",\"content\":\"Transforming cancer treatment by enhancing immunotherapy. At Teclison, we develop innovative cancer therapies to induce tumor necrosis and enhance antitumor immunity, offering patients with liver metastasis the hope of longer, better lives.\"}],[\"$\",\"meta\",\"16\",{\"name\":\"twitter:image\",\"content\":\"https://storage.googleapis.com/teclison/teclison_og_twitter.webp\"}],[\"$\",\"link\",\"17\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"64x64\"}],[\"$\",\"meta\",\"18\",{\"name\":\"next-size-adjust\"}]]\n"])</script><script>self.__next_f.push([1,"5:null\na:E{\"digest\":\"NEXT_NOT_FOUND\"}\n"])</script><script>self.__next_f.push([1,"18:I[9819,[\"739\",\"static/chunks/739-b88516ffa221270f.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"641\",\"static/chunks/641-e7a5c0801ce7e4bd.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"173\",\"static/chunks/173-89ea13df4be38b47.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"61\",\"static/chunks/app/%5Blocale%5D/page-6efb1ebf90caf47b.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\"],\"default\"]\n19:I[1458,[\"739\",\"static/chunks/739-b88516ffa221270f.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"641\",\"static/chunks/641-e7a5c0801ce7e4bd.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"173\",\"static/chunks/173-89ea13df4be38b47.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"61\",\"static/chunks/app/%5Blocale%5D/page-6efb1ebf90caf47b.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\"],\"default\"]\n1a:I[11,[\"739\",\"static/chunks/739-b88516ffa221270f.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"641\",\"static/chunks/641-e7a5c0801ce7e4bd.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"173\",\"static/chunks/173-89ea13df4be38b47.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"61\",\"static/chunks/app/%5Blocale%5D/page-6efb1ebf90caf47b.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\"],\"default\"]\n20:I[1623,[\"739\",\"static/chunks/739-b88516ffa221270f.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"641\",\"static/chunks/641-e7a5c0801ce7e4bd.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"388\",\"static/chunks/388-204774a3bd680b0e.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"87\",\"static/chunks/87-50964c012cdbcc46.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"37\",\"static/chunks/37-7632bd83dfac892b.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"127\",\"static/chunks/127-4d132918bd15c208.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"838\",\"static/chunks/838-9def55325fb42095.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"203\",\"static/chunks/app/%5Blocale%5D/layout-e2527dbbdf6fc00c.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\"],\"default\"]\n30:I[2578,[\"739\",\"static/chunks/739-b88516ffa221270f.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"641\",\"static/chunks/641-e7a5c0801ce7e4bd.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"388\",\"static/chunks/388-204774a3bd680b0e.js?dpl=dpl_3"])</script><script>self.__next_f.push([1,"KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"87\",\"static/chunks/87-50964c012cdbcc46.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"37\",\"static/chunks/37-7632bd83dfac892b.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"127\",\"static/chunks/127-4d132918bd15c208.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"838\",\"static/chunks/838-9def55325fb42095.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\",\"203\",\"static/chunks/app/%5Blocale%5D/layout-e2527dbbdf6fc00c.js?dpl=dpl_3KxN4oVkPje7fMUSYkGf6hrTDnFp\"],\"default\"]\n11:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/about-us\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"children\":[\"$\",\"$L19\",null,{\"className\":\"w-fit\",\"variant\":\"primary\",\"children\":\"About Us\"}]}]\n13:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"our-approach\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"children\":[\"$\",\"$L19\",null,{\"className\":\"w-fit\",\"variant\":\"primary\",\"children\":\"Our Approach\"}]}]\n14:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/pipeline\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"children\":[\"$\",\"$L19\",null,{\"className\":\"w-fit\",\"variant\":\"primary\",\"children\":\"Our Pipeline\"}]}]\n15:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/about-us/#careers\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"children\":[\"$\",\"$L19\",null,{\"className\":\"w-fit\",\"variant\":\"primary\",\"children\":\"Join Us\"}]}]\n16:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/contact\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"children\":[\"$\",\"$L19\",null,{\"className\":\"w-fit\",\"variant\":\"primary\",\"children\":\"Get in Touch\"}]}]\n1b:T4e5,Diane Lu, CPA, is the Chief Financial Officer at Teclison. Since the company’s inception in 2013, she has served in several leadership roles that have been critical to establishing Teclison as an emerging clinical-stage player in the oncology space. Her career spans 30 years of varied experience in corporate strategy, financial management and business development. Diane is responsible for the company"])</script><script>self.__next_f.push([1,"’s financial functions including corporate finance, accounting, investor relations, risk management, and negotiation of licensing deals. In this role, she has fostered strategic collaborations with Merck and out-licensing deal of Teclison’s lead asset, TEC-001, and secured a multi-million-dollar capital raise to further advance it into the clinic. Previously, Diane founded DCL, LLC., a consulting firm, where she provided financial and strategic guidance to companies on a range of business initiatives, including program management, accounting \u0026 tax planning, and regulatory compliance. Prior to DCL, LLC., she also founded a CPA firm and consulted with Ernst \u0026 Young and Arthur Anderson. Diane holds a Master of Accountancy from the Weatherhead School of Management at Case Western Reserve University. She is a Certified Public Accountant.1c:T50d,Dr. Ruffolo is the retired President of Research \u0026 Development of Wyeth Pharmaceuticals and Senior Vice President of the Wyeth Corporation (now Pfizer). At Wyeth, he managed an R\u0026D organization of 9,000 scientists and an annual budget of $3 billion. He received numerous awards during his long career. He was awarded the prestigious John Jacob Abel Award by the American Society for Pharmacology and Experimental Therapeutics (ASPET), and he was recognized in by the Pharmaceutical Research and Manufacturers of America (PhRMA) with their highest award, the Discoverer’s Award, for his pioneering research on the discovery and development of carvedilol (Coreg®). Carvedilol has become the standard of care for the treatment of congestive heart failure. He was named Chief Scientific Officer of the Year by IBC Conferences, and under his leadership of Research and Development, his Executive Team (RADEX) received the Scrip Award for Management Team of the Year. He was the recipient of two Honorary Doctorates (West Virginia University and University of Catania, Italy) and two Lifetime Achievement Awards (Ohio State University and Scrip Awards). He has published in excess of 500 full-len"])</script><script>self.__next_f.push([1,"gth papers, edited 15 books and was the Editor-in-Chief of four international pharmacology journals.1d:T40e,Dr. Scott Antonia is the Director, Center for Cancer Immunotherapy at Duke Cancer Institute, and Professor of Medicine at Duke University, where he is a lung cancer physician. He leads Center for Cancer Immunotherapy of Duke Cancer Institute to look for cancer immunotherapy discoveries that show promise in any cancer types. He works with the original investigator to accelerate the finding into a drug that can be tested in a clinical trial. The team members help accomplish all the tasks required to take a finding to human trials, from conducting additional lab studies, to designing a clinical trial, and even manufacturing a drug. Prio to joining Duke University, he was at Moffitt Cancer Center developing immunotherapies to fight lung cancer, including one that in June 2019 changed the standard of care for stage III non-small-cell lung cancer. He completed Medical Oncology Fellowship and Internal Medicine Residency at Yale University School of Medicine. He received M.D., Ph.D. at University of Connecticut School of Medicine.1e:T54d,Dr. David K. Imagawa is a professor of surgery at the University of California, Irvine Medical Center (UCI Health) and a leading expert in minimally invasive liver and pancreatic surgery. He currently serves as Chief of the Division of Hepatobiliary and Pancreas Surgery and is the Suzanne Dykema Endowed Chair in Pancreatic Cancer at UCI Health. His clinical interests include pancreatic cancer, liver cancer, bile duct cancer and islet cell transplantation. He has over 130 publications and has participated in numerous clinical trials involving hepatocellular carcinoma and pancreatic malignancies. He also is a three-time recipient of the John E. Connolly Award, which is presented annually to an outstanding professor of surgery at the University of California, Irvine School of Medicine. Dr. Imagawa earned a medical degree and a PhD in pharmacology from Johns Hopkins School of Medicine "])</script><script>self.__next_f.push([1,"in Baltimore, MD. He completed an internship and residency in general surgery at the UCLA School of Medicine, and subsequently completed a research fellowship in liver transplantation and a surgical fellowship in organ transplantation. Dr. Imagawa also currently serves on the Clinical Trials Committee of The Americas Hepato-Pancreatico-Biliary Association (AHPBA). He is the most recent recipient of the Liver Wellness Foundation’s Lifetime Achievement Award.1f:T427,Dr. Mark Lemmon is the Alfred Gilman Professor of Pharmacology, Deputy Director of Yale Cancer Center, and Co-Director of Yale Cancer Biology Institute. He returned to Yale as the David A. Sackler Professor of Pharmacology in 2015 after 19 years on the faculty at the University of Pennsylvania’s Perelman School of Medicine. At University of Pennsylvania, he was the George W. Raiziss Professor of Biochemistry and Biophysics as well as Chair of the department and an Investigator at the Abramson Family Cancer Research Institute. Dr. Lemmon was elected as a Fellow of the Royal Society of the United Kingdom in 2016, and honored with the Dorothy Crowfoot Hodgkin Award of the Protein Society and the Stanley N. Cohen Biomedical Research Award from the University of Pennsylvania. He is on the Editorial Advisory Boards of several journals, including Cell and Molecular Cell, and is Chair of the Editorial Board of the Biochemical Journal. Dr. Lemmon received his Ph.D. of Biophysics and Biochemistry from Yale University, and BA from University of Oxford, UK.22:T11a4,"])</script><script>self.__next_f.push([1,"M154.862 21.103a11.3 11.3 0 0 1-1.839 6.45 8.05 8.05 0 0 1-5.991 3.667 10.5 10.5 0 0 1-3.311-.121 4.72 4.72 0 0 1-4.14-4.416 11.38 11.38 0 0 1 2.15-8.168 7.92 7.92 0 0 1 5.677-3.2 9.9 9.9 0 0 1 3.687.222 4.745 4.745 0 0 1 3.759 4.51c.026.35 0 .7 0 1.053m-4.12.12c-.018-.171-.04-.466-.083-.758a2.18 2.18 0 0 0-2.29-2.027 3.59 3.59 0 0 0-3.277 1.825 8.78 8.78 0 0 0-1.334 5.824 2.045 2.045 0 0 0 1.87 1.954c.421.057.848.049 1.266-.026a3.7 3.7 0 0 0 2.469-1.823 9.67 9.67 0 0 0 1.379-4.968M167.572 31.046c-.389-.03-.8-.038-1.2-.1-.594-.09-.719-.28-.6-.87.342-1.7.7-3.4 1.034-5.1.273-1.395.535-2.792.762-4.194a3 3 0 0 0-.07-1.095 1.1 1.1 0 0 0-1.2-.924c-.559.013-1.1.2-1.547.537a7.07 7.07 0 0 0-2.765 3.913c-.251.827-.388 1.69-.563 2.538-.3 1.464-.6 2.928-.879 4.4a.814.814 0 0 1-.694.748 8 8 0 0 1-2.868.028c-.5-.085-.583-.26-.477-.79q1.1-5.484 2.195-10.966c.189-.94.4-1.879.563-2.823a.75.75 0 0 1 .714-.718q1.105-.078 2.21-.022c.5.033.6.26.494.774-.106.515-.222 1.007-.328 1.511a.6.6 0 0 0 .025.19c.061-.029.142-.04.178-.088a7.1 7.1 0 0 1 1.7-1.58 6.25 6.25 0 0 1 4.3-1.117 3.45 3.45 0 0 1 3.193 3.452 11.4 11.4 0 0 1-.273 3.136c-.539 2.7-1.087 5.391-1.629 8.087-.149.742-.328.917-1.1 1-.386.041-.775.054-1.181.081M81.066 25.945a12.5 12.5 0 0 1 2.156-7.211 8.07 8.07 0 0 1 7.653-3.461 7 7 0 0 1 2.359.572 3.9 3.9 0 0 1 .62 6.853 8.8 8.8 0 0 1-3.334 1.29 22.3 22.3 0 0 1-4.42.324 5 5 0 0 0-.665.011.3.3 0 0 0-.213.186c-.19.776-.16 1.59.089 2.349a2.08 2.08 0 0 0 1.93 1.345 10.9 10.9 0 0 0 4.216-.5c.354-.106.7-.239 1.054-.343.6-.176.827-.015.761.589q-.09.742-.277 1.465a1.47 1.47 0 0 1-1.095 1.143c-.821.212-1.642.443-2.478.574-1.48.258-2.996.24-4.471-.05a7 7 0 0 1-.958-.273 4.29 4.29 0 0 1-2.862-3.811c-.05-.4-.05-.811-.064-1.053m6.291-4.245.01.065c.783-.111 1.577-.176 2.345-.351.464-.117.901-.32 1.29-.6a1.38 1.38 0 0 0 .59-1.5 1.41 1.41 0 0 0-1.184-1.1 3.29 3.29 0 0 0-2.91.687 5.14 5.14 0 0 0-1.58 2.485c-.07.208-.014.313.22.311.406-.005.813 0 1.219 0M77.143 10.29h7.165a.436.436 0 0 1 .468.445 5 5 0 0 1-.557 2.622.83.83 0 0 1-.846.4 368 368 0 0 0-4.33 0c-.513 0-.517 0-.622.526l-3.089 15.474c-.189.947-.37 1.145-1.344 1.2-.7.043-1.4.009-2.105.008a1.2 1.2 0 0 1-.22-.025c-.653-.12-.77-.284-.64-.946q.618-3.123 1.244-6.244l1.914-9.554c.086-.431.084-.44-.347-.441h-4.386c-.587 0-.769-.141-.706-.718.07-.678.204-1.348.4-2 .2-.65.422-.751 1.116-.752h6.884M130.001 31.3a9.1 9.1 0 0 1-3.044-.553c-1.232-.46-1.434-.833-1.16-2.1q.116-.57.336-1.11c.2-.474.42-.52.874-.277q.764.449 1.578.8a4.7 4.7 0 0 0 2.892.136 1.8 1.8 0 0 0 1.434-1.631 1.15 1.15 0 0 0-.441-1.078 8 8 0 0 0-.977-.627c-.569-.306-1.169-.557-1.73-.876a3.69 3.69 0 0 1-2.029-4.411 4.91 4.91 0 0 1 3.5-3.873 8.6 8.6 0 0 1 5.872.089q.258.101.5.238a.76.76 0 0 1 .365.333c.081.15.109.32.081.488a13 13 0 0 1-.436 1.82c-.143.433-.362.487-.785.308-.357-.151-.7-.346-1.057-.487a4.4 4.4 0 0 0-2.715-.266 1.78 1.78 0 0 0-1.457 1.42 1 1 0 0 0 .377 1.084q.566.398 1.18.718c.7.379 1.432.7 2.1 1.113a3.62 3.62 0 0 1 1.678 3.97 5.3 5.3 0 0 1-3.936 4.355 9.3 9.3 0 0 1-3 .42M97.094 25.891a12.76 12.76 0 0 1 2.467-7.653 7.45 7.45 0 0 1 6.872-2.94c.889.049 1.756.29 2.543.705q.35.171.622.452c.153.178.248.4.27.633a4.4 4.4 0 0 1-.453 2.091c-.378.8-.878.722-1.35.3a3.46 3.46 0 0 0-2.036-.919 3.25 3.25 0 0 0-3.043 1.363 8 8 0 0 0-.957 1.735 9.2 9.2 0 0 0-.708 3.948q.02.415.126.818a1.88 1.88 0 0 0 1.747 1.457 4.67 4.67 0 0 0 2.926-.643c.271-.159.532-.334.8-.5q.184-.123.387-.213c.408-.16.581-.048.631.4a.7.7 0 0 1 0 .221c-.146.7-.278 1.409-.454 2.1a1.61 1.61 0 0 1-.8.956 7.5 7.5 0 0 1-2.535.929 8.2 8.2 0 0 1-3.576-.077 4.3 4.3 0 0 1-3.357-3.823c-.07-.492-.1-.99-.13-1.342M112.224 31.058c-.536-.048-.983-.057-1.418-.134-.5-.09-.609-.274-.509-.772q1.207-6.055 2.419-12.111.8-4.02 1.607-8.037c.2-.992.355-1.162 1.378-1.223.607-.036 1.219-.01 1.829 0q.223.009.435.076c.452.132.547.259.468.724-.111.655-.252 1.305-.382 1.957a20429 20429 0 0 0-3.392 17c-.112.56-.233 1.12-.332 1.684a.696.696 0 0 1-.6.642c-.527.088-1.061.138-1.5.194M120.196 31.057c-.484-.043-.95-.053-1.4-.131-.5-.087-.6-.264-.5-.778q1.353-6.84 2.7-13.683a.905.905 0 0 1 .775-.814 7.3 7.3 0 0 1 2.755-.017c.556.1.643.273.534.818q-1.364 6.84-2.723 13.679a.83.83 0 0 1-.736.77c-.474.068-.953.107-1.411.157M123.549 13.547q-.572-.063-1.134-.187a.94.94 0 0 1-.763-.965 4.2 4.2 0 0 1 .4-1.991 1.82 1.82 0 0 1 1.415-1.046 5.3 5.3 0 0 1 1.988-.007 1.1 1.1 0 0 1 1.005.819q.06.227.022.458a7.5 7.5 0 0 1-.29 1.517 1.8 1.8 0 0 1-1.524 1.288c-.345.06-.7.073-1.121.114M22.423 5.644V0L0 22.424l22.423 22.423v-4.756L5.2 22.868z"])</script><script>self.__next_f.push([1,"17:[\"$\",\"$L1a\",null,{\"locale\":\"en-US\",\"now\":\"$D2025-02-07T23:59:15.245Z\",\"timeZone\":\"UTC\",\"messages\":{\"metadata\":{\"title\":\"Teclison | Transforming cancer treatment by enhancing immunotherapy\",\"description\":\"At Teclison, we develop innovative cancer therapies to induce tumor necrosis and enhance antitumor immunity, offering patients with liver metastasis the hope of longer, better lives.\",\"open_graph_title\":\"Teclison | Transforming cancer treatment by enhancing immunotherapy\",\"open_graph_description\":\"Transforming cancer treatment by enhancing immunotherapy. At Teclison, we develop innovative cancer therapies to induce tumor necrosis and enhance antitumor immunity, offering patients with liver metastasis the hope of longer, better lives.\",\"twitter_title\":\"Teclison | Transforming cancer treatment by enhancing immunotherapy\",\"twitter_description\":\"Transforming cancer treatment by enhancing immunotherapy. At Teclison, we develop innovative cancer therapies to induce tumor necrosis and enhance antitumor immunity, offering patients with liver metastasis the hope of longer, better lives.\"},\"navbar\":{\"about_us\":\"About Us\",\"our_approach\":\"Our Approach\",\"pipeline\":\"Pipeline\",\"contact\":\"Contact\",\"in_the_news\":\"In the News\"},\"footer\":{\"company_title\":\"Company\",\"company_about_us\":\"About Us\",\"company_leadership\":\"Leadership\",\"company_scientific_advisors\":\"Scientific Advisors\",\"company_careers\":\"Careers\",\"company_contact\":\"Contact\",\"science_title\":\"Science\",\"science_our_approach\":\"Our Approach\",\"science_pipeline\":\"Pipeline\",\"science_indications\":\"Indications\",\"science_publications\":\"Publications\",\"science_clinical_trials\":\"Clinical Trials\",\"footer_links_privacy_policy\":\"Privacy \u0026 Cookies Policy\",\"footer_links_accessibility\":\"Accessibility\",\"address_nj\":\"New Jersey:\\n100 Overlook Center\\n2nd Floor\\nPrinceton, NJ 08540\",\"address_taiwan\":\"Taiwan:\\n7-1, No. 57, Fuxing N. Road, Songshan District\\nTaipei, Taiwan, R.O.C. 105404\",\"address_email\":\"[email protected]\",\"footer_copy_right\":\"© 2024 Teclison Limited. All rights reserved.\"},\"cta\":{\"message_prompt\":\"Questions? Send us a message.\",\"button\":\"Contact Us\"},\"pagination\":{\"no_articles\":\"No articles found.\",\"content\":\"Page {current} of {total}\"},\"homepage\":{\"key_visual\":{\"title\":\"Transforming cancer treatment by enhancing immunotherapy\",\"subtitle\":\"We develop innovative cancer therapies to induce tumor necrosis and enhance antitumor immunity, offering cancer patients the hope of longer, better lives.\",\"btn_content\":\"About Us\"},\"our_approach\":{\"title\":\"Our Approach\",\"subtitle\":\"Our innovative platform radically remodels the tumor immune microenvironment of solid cancers, unlocking the ability to successfully treat cancer patients who respond poorly to existing immunotherapies.\",\"btn_content\":\"Our Approach\"},\"our_pipeline\":{\"title\":\"Our Pipeline\",\"subtitle\":\"Our innovative approaches aim to enhance immune checkpoint inhibitors (ICIs) and prolong the lives of patients with solid tumor cancers that have metastasized to the liver.\",\"btn_content\":\"Our Pipeline\",\"callout\":\"\\\"We believe in our pipeline's ability to enhance and achieve long-term remission for patients\\\"\"},\"career_and_contact\":{\"career_title\":\"Careers\",\"career_subtitle\":\"Every day, we are exploring new ways to improve the lives of patients with solid tumor cancers. Join our growing team of experts.\",\"career_btn_content\":\"Join Us\",\"contact_title\":\"Contact Us\",\"contact_subtitle\":\"For questions regarding partnership opportunities, investor relations, media coverage, or other inquiries, please reach out to us.\",\"contact_btn_content\":\"Get in Touch\"}},\"about_us\":{\"heading\":\"Who We Are\",\"subheading\":\"Together, we are rewriting the future for thousands of patients and their families\",\"paragraph_1\":\"Our science and our culture are built on strategic collaboration and a deep commitment to improve treatment options for patients with cancer.\",\"paragraph_2\":\"We are on a mission to close critical gaps in cancer care by developing therapies that target well-understood biological pathways in which research has not yet yielded effective medicines.\",\"paragraph_3\":\"Our scientists, advisors, and other experts leverage scientific innovation with pharmaceutical expertise to engineer groundbreaking therapies for solid tumor cancers with historically poor prognoses. Our deep understanding of the tumor microenvironments, as well as our enduring commitment to optimal patient outcomes, guide us to combine our platform with therapeutic agents to achieve durable remissions.\",\"innovation_graphic_label\":\"Where Scientific Innovation\u003cbr\u003e\u003c/br\u003eMeets Pharmaceutical Expertise\",\"team\":{\"leadership_heading\":\"Leadership\",\"advisors_heading\":\"Scientific Advisors\",\"team_page_button\":\"Our Team\",\"leaderships\":{\"ray_lee\":{\"name\":\"Ray Lee, MD, PhD\",\"title\":\"Founder, Chief Executive Officer, Chief Medical Officer\",\"description\":\"Ray Lee is a recognized leader in medical oncology with more than 20 years of experience as a university faculty member and clinical development leader at Merck and Roche as Senior Director. With extensive experience in designing large-scale clinical development plans, Ray has successfully led teams for NDA filing and application of Breakthrough Therapy Designation. He is a patent inventor and board-certified medical oncologist in the United States. He completed a medical oncology fellowship at the University of Washington and an Internal Medicine residency at Duke University Medical Center. Ray holds a Ph.D. in Biochemistry from Duke University and an M.D. from National Taiwan University.\"},\"diane_lu\":{\"name\":\"Diane Lu\",\"title\":\"Chief Financial Officer\",\"description\":\"$1b\"},\"kuenhi_tsai\":{\"name\":\"Kuenhi Tsai, PhD\",\"title\":\"Senior Vice President of Clinical Research\",\"description\":\"Kuenhi Tsai has extensive pharmaceutical and biometrics experiences providing for late-stage clinical development, early-stage clinical pharmacology, post-market research, and pre-clinical discovery with more than 23 years working at major, small, and CRO pharmaceutical companies. He was involved in life-cycle management discussion for multiple companies. He developed innovative designs for both early and late phase studies and led Modeling and Simulation projects, data analysis for NDA filing. He was a director of Merck and represented the company in multiple pharma working groups. He received his Ph.D. in dual majors, Biomathematics and Statistics, from North Carolina State University, M.S. from University of Montana.\"},\"robert_ruffolo\":{\"name\":\"Robert R. Ruffolo, PhD\",\"title\":\"Scientific and Strategic Advisor\",\"description\":\"$1c\"}},\"advisors\":{\"scott_antonia\":{\"name\":\"Scott Antonia, MD, PhD\",\"description\":\"$1d\"},\"david_imagawa\":{\"name\":\"David K. Imagawa, MD, PhD\",\"description\":\"$1e\"},\"mark_lemmon\":{\"name\":\"Mark A. Lemmon, PhD, FRS\",\"description\":\"$1f\"}}},\"partners\":{\"heading\":\"Partners\",\"paragraph\":\"We have forged collaborations with top-tier companies, partnering with Merck to develop our treatment platform. We are committed to pioneering new ways to effectively treat patients with solid tumor cancers who respond poorly to existing immunotherapies.\",\"button\":\"Partner With Us\"},\"careers\":{\"heading\":\"Careers\",\"paragraph\":\"Our team works at the leading edge of cancer immunotherapy, and we are committed to changing patient outcomes for the better. If you are interested in joining our team of passionate collaborators who are giving patients with solid tumor cancers the hope of lasting remission, we encourage you to apply.\",\"button\":\"Explore Open Positions\"}},\"our_approach_page\":{\"key_visual\":{\"title\":\"A Novel Approach to Treating Solid Tumor\"},\"achievements\":{\"five_year_survival_rate\":{\"content\":\"Primary liver cancer, particularly hepatocellular carcinoma (HCC), is a significant health challenge. In the United States, it is estimated that about 41,630 new cases of liver cancer will be diagnosed in 2024, with approximately 29,840 deaths expected. The survival rate remains low, a 5-year survival rate of about 20%. Immunotherapy has become a crucial treatment for advanced liver cancer based on clinical trials demonstrating an improved survival compared to previous treatments. However, once patients fail immunotherapy, there are almost no effective medications. Development of new therapeutic agents is critical.\",\"title\":\"Survival over 5 years\",\"subtitle\":\"in patients with cancers that have metastasized to the liver\"},\"mcrc\":{\"content_title\":\"Many patients will face Liver metastasis…\",\"content\":\"Most patients with metastatic colorectal cancer (mCRC)—the third most common cancer in men and the second most common cancer in women—will face liver metastasis. Of these, only 4% with DNA mismatch repair defects respond to anti-PD-1 ICIs. The remaining 96% of patients with mCRC are treated with conventional chemotherapy along with targeted agents, such as VEGF or EGFR inhibitors.\",\"title\":\"mCRC IS THE\",\"first_rate_sub\":\"most common cancer in men\",\"second_rate_sub\":\"most common cancer in women\",\"conj\":\"and\"},\"chance_of_response\":{\"content_title\":\"But have limited treatment options\",\"content\":\"Once these patients have failed 2 lines of chemotherapy, their chance of responding to additional chemotherapy or immunotherapy hovers around 2%, with a median overall survival of 7 months. This leaves a cohort of patients with mCRC in need of a more effective treatment approach.\",\"title\":\"Chance of response\",\"subtitle\":\"in patients with cancers that have metastasized to the liver\"},\"lung_cancer\":{\"content_title\":\"From Lung to Liver, Options Are Limited\",\"content\":\"Approximately 30% of patients with lung cancer—the second most common cancer— face liver metastasis with a poor prognosis and limited response to anti-PD-1 ICIs. Those whose cancers progress after treatment with a suitable targeted agent face diminishing returns with additional aggressive chemotherapy and need a better approach.\",\"title\":\"of patients with lung cancer\",\"subtitle\":\"face liver metastasis and diminishing returns\"}},\"anti_cancer_content\":{\"title\":\"Anticancer Immunity\",\"subtitle\":\"By Inducing solid tumor necrosis, We take a different approach\",\"paragraph_1\":\"Because the liver's strong immune-suppressive environment protects metastatic tumors, current chemotherapies lead the body to develop immune tolerance to the tumor by activating M2 macrophages (immune cells with high immunosuppressive functions). In contrast, when M1 macrophages are activated, they present tumor antigens to the immune system and can induce robust and durable antitumor immunity.\",\"paragraph_2\":\"We have pioneered a new strategy that avoids apoptosis and induces tumor necrosis. In doing so, we induce M1 inflammation, attracting extra-hepatic M1 macrophages to the necrotic tumor. This novel approach works with FDA-approved ICIs to induce solid tumor necrosis and boost anticancer immunity.\",\"paragraph_3\":\"Our novel hypoxia-activating agent is delivered directly to the tumor through a tumor-feeding artery, creating a hypoxic environment optimal for tumor necrosis. Optimizing the tumor microenvironment for drug activation offers the potential to reach more patients.\",\"paragraph_4\":\"This necrosis-triggered inflammation then utilizes macrophages that present tumor-specific antigens to key immune cells. The anticancer immune response works synergistically with an ICI to target other cancer cells throughout the body, including cancer stem cells. Our novel approach can offer immunity against future cancer cell growth and promote lasting remission.\",\"video_description\":\"Teclison's novel, hypoxia-activating agent enables tumor necrosis to reduce liver tumor burden and stimulate the immune system to generate antitumor T-cells that help fight cancer throughout the body.\"},\"key_clinical_evidence\":{\"title\":\"Key Clinical Evidence\",\"subtitle_1\":\"enhanced efficacy\",\"paragraph_1\":\"Complete tumor necrosis occurred in 60% of patients with intermediate-stage liver cancer treated with our transarterial embolization (TATE) platform therapy, resulting in 52 months of survival compared with 20 to 24 months in those treated with standard of care (SOC).\",\"subtitle_2\":\"TATE combined with immune checkpoint inhibitors\",\"paragraph_2\":\"Scientists are actively exploring new treatments that can work synergistically with immunotherapy to enhance its effectiveness and provide options for cancer patients who are resistant to current immune checkpoint inhibitors. TATE has shown potential in achieving this goal. In clinical trials investigating the combination of TATE and immunotherapy, patients not only saw resolution of liver lesions but also experienced tumor reduction in other parts of the body. The frequent observation of clinical responses outside the liver in patients treated with TATE and immunotherapy supports the hypothesis that TATE can enhance the efficacy of immune checkpoint inhibitors.\",\"subtitle_3\":\"proven safety\",\"paragraph_3\":\"Our treatment is only activated under the low-oxygen (hypoxic) condition of a tumor, rendering it harmless to healthy tissues. This approach was well-tolerated in patients with no serious drug-related adverse events reported.\",\"go_to_action\":\"To learn more about our clinical trials, read our publications.\",\"cta_button\":\"Publications\"}},\"contact\":{\"heading\":\"Contact\",\"subheading\":\"We'd love to hear from you.\",\"name\":{\"label\":\"Name\",\"placeholder\":\"John Doe\"},\"subject\":{\"label\":\"Subject\",\"placeholder\":\"Select Subject\",\"options\":{\"general\":\"General inquiries\",\"media\":\"Media inquiries\",\"career\":\"Career inquiries\",\"partnership\":\"Partnership inquiries\"}},\"message\":{\"label\":\"Message\",\"placeholder\":\"Enter your message...\"},\"send_button\":\"Send Message\",\"address\":{\"label\":\"Address\",\"nj\":\"New Jersey:\u003cbr\u003e\u003c/br\u003e100 Overlook Center\u003cbr\u003e\u003c/br\u003e2nd Floor\u003cbr\u003e\u003c/br\u003ePrinceton, NJ 08540\",\"taiwan\":\"Taiwan:\u003cbr\u003e\u003c/br\u003e7-1, No. 57, Fuxing N. Road, Songshan District\u003cbr\u003e\u003c/br\u003eTaipei, Taiwan, R.O.C. 10489\"},\"email\":{\"label\":\"Email\",\"value\":\"[email protected]\"}},\"pipeline\":{\"heading\":\"Pipeline\",\"sections\":{\"tec_001\":{\"title\":\"TEC-001\",\"description\":\"TEC-001 with transarterial embolization (TATE) uses a well-established procedure to shut off blood supply to the tumor to create the hypoxic environment necessary for drug activation. TATE has the potential to enhance the efficacy of FDA-approved immune checkpoint inhibitors (ICIs) and transform the standard of care for patients battling cancer. TEC-001 works with ICIs to generate a systemic anticancer immune response that can target cancer cells throughout the body. This durable anticancer immunity helps safeguard against future cancer growth and promote lasting remission.\"},\"tec_002\":{\"title\":\"TEC-002\",\"description\":\"Our second pipeline, TEC-002 induces tumor death and presents tumor antigen to the immune system. This process activates the body's immune system, enabling it to recognize tumors as foreign substances and generate an immune response against them. TEC-002 is designed for use with all solid tumors and is anticipated to have broad applications.\"},\"tec_003\":{\"title\":\"TEC-003\",\"description\":\"Our third pipeline, TEC-003, is triggered after TEC-001 or TEC-002 treatment by harnessing the physiological immune response. This approach leverages the patient's own immune system to target tumors, serving as a potent therapeutic strategy to combat cancer. It has the potential to collaboratively target multiple tumor antigens, maximizing its effectiveness.\"}},\"pipeline_data\":{\"fda_meeting_label\":\"FDA\u003cbr\u003e\u003c/br\u003eMeeting\",\"progress_headers\":{\"preclinical\":\"Preclinical\",\"phase_1\":\"Phase 1\",\"phase_2\":\"Phase 2\",\"collaborator\":\"Collaborator\"},\"items\":{\"item_1\":{\"subtitle\":\"+Keytruda\",\"indication\":\"COLORECTAL CANCER\",\"subindication\":\"\"},\"item_2\":{\"subtitle\":\"\",\"indication\":\"LIVER CANCER\",\"subindication\":\"Intermediate stage\"},\"item_3\":{\"subtitle\":\"+Opdivo\",\"indication\":\"LIVER CANCER\",\"subindication\":\"Advanced stage\"},\"item_4\":{\"subtitle\":\"+Keytruda\",\"indication\":\"LUNG CANCER\",\"subindication\":\"\"},\"item_5\":{\"subtitle\":\"+Opdivo\",\"indication\":\"STOMACH CANCER\",\"subindication\":\"\"},\"item_6\":{\"subtitle\":\"\",\"indication\":\"NEUROENDOCRINE TUMOR\",\"subindication\":\"\"},\"item_7\":{\"subtitle\":\"\",\"indication\":\"SOLID TUMORS\",\"subindication\":\"\"},\"item_8\":{\"subtitle\":\"\",\"indication\":\"SOLID TUMORS\",\"subindication\":\"\"}}},\"indications\":{\"heading\":\"Indications\",\"paragraph_1\":\"Teclison is preparing to launch its first pipeline product, TATE, for advanced hepatocellular carcinoma (HCC). Currently in phase 2 clinical trials, TATE has shown promising preliminary results in patients with advanced HCC who have not responded to immunotherapy. This result will support advanced HCC as the first indication for TATE. Additionally, phase 2 trials are underway for other cancers, including lung, gastric, colorectal, and neuroendocrine tumors.\",\"paragraph_2\":\"Teclison is actively expanding its treatment indications to target a wider range of cancer types with its highly specific, tumor-targeting strategy, providing new hope for patients who have developed resistance to standard treatments.\",\"future_indications\":\"Targeted Future Indications\",\"our_pipeline_heading\":\"Our Pipeline\",\"our_pipeline_paragraph\":\"Our approaches promise novel treatments for solid tumors, extending lives and challenge current treatment paradigm for patients who have exhausted treatment options.\"}},\"privacy_policy\":{\"title\":\"Privacy Policy\",\"introduction_1\":\"Teclison, Inc. (Teclison) respects the privacy of visitors to our website and is committed to protecting their personal information. This privacy policy explains the data collected and the practices of Teclison's website.\",\"introduction_2\":\"Description of the information Teclison may collect on our website:\",\"sections\":{\"personally_identifiable_information\":{\"title\":\"Personally Identifiable Information\",\"paragraph_1\":\"Teclison collects personal identifiable information (i.e., information from which you can be identified, such as your name) only when it is asked for or you voluntarily submit it to our website. We may use the information to respond to your requests, improve our service and the content of our website, provide you with helpful information, news and updates; notify you of our products and services; and for Teclison's own internal purposes.\"},\"non_personally_identifiable_information\":{\"title\":\"Non-Personally Identifiable Information\",\"paragraph_1\":\"Teclison may also collect non-personally identifiable information in an aggregate form to track data such as the number of visits to our website, the number of visitors to each page of our website and the domain names of our visitors' internet service providers. We use this information, which remains in a non-personally identifiable form, to understand how our visitors use our website so that we may improve our website and the services we offer.\"},\"ip_addresses\":{\"title\":\"Use of IP Addresses\",\"paragraph_1\":\"An Internet Protocol (IP) address is a set of numbers that is automatically assigned to your computer whenever you log on to your internet service provider or through your organization's local area network (LAN) or wide area network (WAN). Web servers automatically identify your computer by the IP address assigned to it during your online session.\",\"paragraph_2\":\"Teclison, or third-party companies acting on behalf of Teclison, may collect IP addresses for the purposes of systems administration and to audit the use of our website. We do not link a user's IP address to personal identification information of that user, which means each user's session will be logged, but the user remains anonymous to us. However, we may use IP addresses to identify users of our website when we feel it is necessary to enforce compliance with the website's terms of use or to protect our service, website or other users.\"},\"sharing_information\":{\"title\":\"Sharing Personally Identifiable Information with Third Parties\",\"paragraph_1\":\"Teclison will not sell or rent personally identifiable information to any third party for any purpose. Third parties may be used by Teclison to provide support services for our website and such parties may have access to your information so that they can provide the necessary services to Teclison. Please be assured that any companies that provide such support services are required by Teclison to meet the data protection standard and are prohibited from using the information for purposes non-related to Teclison.\"},\"links_to_other_websites\":{\"title\":\"Links to Other Websites\",\"paragraph_1\":\"This website may provide links to Teclison or third-party websites as a service to our users. The privacy statement described here does not apply to the non-Teclison websites. Please check the legal and privacy statement for each website you link to.\"},\"changes\":{\"title\":\"Changes\",\"paragraph_1\":\"We may update this legal and privacy statement any time in the future. We encourage you to periodically review this legal and privacy statement to stay informed about how we protect the personal information we collect. Your continued use of our website constitutes your agreement to the terms and conditions for using our website, our privacy statement and related information.\"}}},\"accessibility_statement\":{\"title\":\"Accessibility Statement\",\"introduction_1\":\"This is an accessibility statement from Teclison Inc.\",\"sections\":{\"conformance_status\":{\"title\":\"Conformance status\",\"paragraph\":\"The \u003clinks\u003eWeb Content Accessibility Guidelines (WCAG)\u003c/links\u003e defines requirements for designers and developers to improve accessibility for people with disabilities. It defines three levels of conformance: Level A, Level AA, and Level AAA. Teclison website is fully conformant with WCAG 2.1 level AA. Fully conformant means that the content fully conforms to the accessibility standard without any exceptions.\"},\"additional_accessibility_considerations\":{\"title\":\"Additional accessibility considerations\",\"paragraph_1\":\"Although our goal is WCAG 2.1 Level AA conformance, we have also applied some Level AAA Success Criteria: Images of text are only used for decorative purposes. Re-authentication after a session expires does not cause loss of data.\"},\"feedback\":{\"title\":\"Feedback\",\"paragraph_1\":\"We welcome your feedback on the accessibility of Teclison website. Please let us know if you encounter accessibility barriers on Teclison website:\",\"contact_email\":\"Email:\",\"email_address\":\"[email protected]\",\"contact_address\":\"Address: 100 Overlook Center, 2nd floor, Princeton, NJ 08540\"}},\"footer\":{\"paragraph_1\":\"This statement was created on 10 August, 2022 using the \u003clinks\u003eW3C Accessibility Statement Generator Tool.\u003c/links\u003e\"}},\"not_found\":{\"title\":\"This page doesn't seem to exist\",\"description\":\"It looks like the link pointing here was faulty. Maybe try searching?\"},\"in_the_news\":{\"title\":\"In the News\",\"subheading\":\"Media Coverage\",\"media_coverage\":{\"item_1\":{\"date\":\"MAR 2023\",\"title\":\"2022 JVIR Editor's Award Honoree / Distinguished Clinical Study, by the Journal of Vascular and Interventional Radiology (JVIR), The flagship journal of Society of Interventional Radiology (SIR)\",\"source\":\"Society of Interventional Radiology\",\"link\":\"#\"},\"item_2\":{\"date\":\"NOV 2022\",\"title\":\"Converting liver tumors into low-oxygen environment to activate drug to drive cell death with Dr. Ray Lee Teclison\",\"source\":\"The Empowered Patient podcast\",\"link\":\"https://empoweredpatientradio.com/converting-liver-tumors-into-low-oxygen-environment-to-activate-drug-to-drive-cell-death-with-dr-ray-lee-teclison-transcript\"},\"item_3\":{\"date\":\"OCT 2022\",\"title\":\"Triggering a systemic immune response against cancer\",\"source\":\"The Bio Report podcast\",\"link\":\"http://thebioreport.com/2022/10/06/triggering-a-systemic-immune-response-against-cancer/\"},\"item_4\":{\"date\":\"SEP 2022\",\"title\":\"World Cancer Research Day highlights innovation in immuno-oncology\",\"source\":\"BioSpace\",\"link\":\"https://www.biospace.com/world-cancer-research-day-highlights-innovation-in-immuno-oncology\"},\"item_5\":{\"date\":\"MAY 2022\",\"title\":\"PharmaShots interview: Teclison's Ray Lee shares insights on the $5.9 million capital raise\",\"source\":\"PharmaShots\",\"link\":\"https://pharmashots.com/7489/pharmashots-interview-teclison%E2%80%99s-ray-lee-shares-insights-on-the-59-million-capital-raise\"},\"item_6\":{\"date\":\"MAR 2022\",\"title\":\"Teclison raises $5.9M to advance solid tumor program\",\"source\":\"BioWorld (paywall)\",\"link\":\"https://www.bioworld.com/articles/516528-teclison-raises-59m-to-advance-solid-tumor-program?v=preview\"},\"item_7\":{\"date\":\"FEB 2022\",\"title\":\"Teclison closes $5.9M funding round\",\"source\":\"FinSMEs\",\"link\":\"https://www.finsmes.com/2022/02/teclison-closes-5-9m-funding-round.html\"}}},\"publications\":{\"title\":\"Publications\",\"article\":{\"item_1\":{\"date\":\"AUG 2022\",\"title\":\"phase i dose-escalation study of tirapazamine chemoembolization for unresectable early- and intermediate-stage hepatocellular carcinoma\",\"source\":\"Chang-Hsien Liu\",\"link\":\"https://www.jvir.org/article/S1051-0443(22)00832-6/abstract\"},\"item_2\":{\"date\":\"AUG 2021\",\"title\":\"phase i trial on arterial embolization with hypoxia activated tirapazamine for unresectable hepatocellular carcinoma\",\"source\":\"Nadine Abi-Jaoudeh\",\"link\":\"https://www.teclison.com/wp-content/uploads/2022/06/Abi-Jaoudeh_J-HCC_2021_Tirapazamine_Phase-1-US-study-HCC.pdf\"},\"item_3\":{\"date\":\"JAN 2021\",\"title\":\"liver metastasis restrains immunotherapy efficacy via macrophage-mediated t cell elimination\",\"source\":\"Jiali Yu\",\"link\":\"https://www.teclison.com/wp-content/uploads/2022/06/Yu_Nat-Med_2021_Liver-Macrophages.pdf\"}}}},\"children\":[[\"$\",\"$L20\",null,{}],[\"$\",\"div\",null,{\"className\":\"flex flex-col items-center justify-center gap-y-5 bg-gray-100 px-5 py-20\",\"children\":[\"$\",\"div\",null,{\"className\":\"lg;px-10 flex w-full flex-col items-center justify-center gap-y-10 bg-white px-4 py-6 md:px-9 lg:py-14 xl:px-[132px] xl:py-[104px]\",\"children\":[[\"$\",\"h1\",null,{\"className\":\"text-center font-normal\",\"children\":\"This page doesn't seem to exist\"}],[\"$\",\"p\",null,{\"className\":\"text-center text-sh3 lg:text-sh2\",\"children\":\"It looks like the link pointing here was faulty. Maybe try searching?\"}]]}]}],[\"$\",\"div\",null,{\"className\":\"flex w-full flex-col items-center justify-center gap-x-12 gap-y-6 bg-light-blue-100 px-4 py-10 md:flex-row md:justify-between md:px-20 md:py-[72px] xl:justify-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-center text-b2 md:text-left md:text-b1\",\"children\":\"Questions? Send us a message.\"}],\"$L21\"]}],[\"$\",\"footer\",null,{\"className\":\"bg-blue py-10\",\"children\":[\"$\",\"div\",null,{\"className\":\"mx-auto max-w-screen-2xl px-4 sm:px-6 lg:px-8\",\"children\":[[\"$\",\"div\",null,{\"className\":\"grid grid-cols-1 gap-3 md:grid-cols-3 lg:grid-cols-4 lg:gap-[50px]\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-col gap-y-8 text-center md:col-span-1 lg:col-span-2 lg:text-left\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-col items-center lg:items-start\",\"children\":[\"$\",\"svg\",null,{\"className\":\"h-12 w-[172px]\",\"fill\":\"none\",\"height\":\"$undefined\",\"viewBox\":\"0 0 172 46\",\"width\":\"$undefined\",\"xmlns\":\"http://www.w3.org/2000/svg\",\"children\":[[\"$\",\"g\",null,{\"clipPath\":\"url(#teclison-logo-white_svg__a)\",\"fill\":\"#fff\",\"children\":[[\"$\",\"path\",null,{\"d\":\"$22\"}],[\"$\",\"path\",null,{\"d\":\"M29.451 7.641V.333l-1.828 1.829-20.76 20.76 20.76 20.759 1.83 1.829v-6.528l-15.67-15.67z\"}],[\"$\",\"path\",null,{\"d\":\"M38.094 6.766v-6l-1.89 1.89-20.7 20.7 20.7 20.7 1.89 1.89v-6.089L21.548 23.311z\"}],[\"$\",\"path\",null,{\"d\":\"m43.972 2.57-20.74 20.74 20.74 20.742 1.682 1.682V.888zM47.437.888v44.038l22.019-22.02z\"}]]}],[\"$\",\"defs\",null,{\"children\":[\"$\",\"clipPath\",null,{\"id\":\"teclison-logo-white_svg__a\",\"children\":[\"$\",\"path\",null,{\"d\":\"M0 0h171.776v45.94H0z\",\"fill\":\"#fff\"}]}]}]]}]}],[\"$\",\"p\",null,{\"className\":\"whitespace-pre-line text-white text-b3\",\"children\":\"New Jersey:\\n100 Overlook Center\\n2nd Floor\\nPrinceton, NJ 08540\"}],[\"$\",\"p\",null,{\"className\":\"whitespace-pre-line text-white text-b3\",\"children\":\"Taiwan:\\n7-1, No. 57, Fuxing N. Road, Songshan District\\nTaipei, Taiwan, R.O.C. 105404\"}],[\"$\",\"p\",null,{\"className\":\"text-white text-b3\",\"children\":\"$L23\"}]]}],[[\"$\",\"div\",\"company_title\",{\"className\":\"text-center text-b3 lg:col-span-1 lg:text-left\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"mb-3 font-bold text-white lg:mb-4\",\"children\":\"Company\"}],[\"$\",\"ul\",null,{\"className\":\"flex flex-col gap-y-3 lg:gap-y-4\",\"children\":[[\"$\",\"li\",\"company_about_us\",{\"children\":\"$L24\"}],[\"$\",\"li\",\"company_leadership\",{\"children\":\"$L25\"}],[\"$\",\"li\",\"company_scientific_advisors\",{\"children\":\"$L26\"}],[\"$\",\"li\",\"company_careers\",{\"children\":\"$L27\"}],[\"$\",\"li\",\"company_contact\",{\"children\":\"$L28\"}]]}]]}],[\"$\",\"div\",\"science_title\",{\"className\":\"text-center text-b3 lg:col-span-1 lg:text-left\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"mb-3 font-bold text-white lg:mb-4\",\"children\":\"Science\"}],[\"$\",\"ul\",null,{\"className\":\"flex flex-col gap-y-3 lg:gap-y-4\",\"children\":[[\"$\",\"li\",\"science_our_approach\",{\"children\":\"$L29\"}],[\"$\",\"li\",\"science_pipeline\",{\"children\":\"$L2a\"}],[\"$\",\"li\",\"science_indications\",{\"children\":\"$L2b\"}],[\"$\",\"li\",\"science_publications\",{\"children\":\"$L2c\"}],[\"$\",\"li\",\"science_clinical_trials\",{\"children\":\"$L2d\"}]]}]]}]]]}],[\"$\",\"div\",null,{\"className\":\"my-5 border-t border-dashed border-[#707070] sm:mt-12 lg:mb-8\"}],[\"$\",\"div\",null,{\"className\":\"flex flex-col items-center justify-around gap-8 text-white sm:flex-row lg:justify-between lg:gap-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"text-center lg:col-span-1 lg:text-left\",\"children\":[\"$\",\"ul\",null,{\"className\":\"flex flex-col gap-3 lg:flex-row lg:gap-4\",\"children\":[[\"$\",\"li\",\"footer_links_privacy_policy\",{\"children\":\"$L2e\"}],[\"$\",\"li\",\"footer_links_accessibility\",{\"children\":\"$L2f\"}]]}]}],[\"$\",\"$L30\",null,{}],[\"$\",\"p\",null,{\"className\":\"text-white text-b3\",\"children\":\"© 2024 Teclison Limited. All rights reserved.\"}]]}]]}]}]]}]\n"])</script><script>self.__next_f.push([1,"21:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/contact\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"children\":[\"$\",\"$L19\",null,{\"size\":\"secondary\",\"variant\":\"secondary\",\"children\":\"Contact Us\"}]}]\n23:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"mailto:address_email\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"children\":\"[email protected]\"}]\n24:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/about-us\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"className\":\"text-white text-b3\",\"children\":\"About Us\"}]\n25:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/about-us#leadership\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"className\":\"text-white text-b3\",\"children\":\"Leadership\"}]\n26:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/about-us#scientific-advisors\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"className\":\"text-white text-b3\",\"children\":\"Scientific Advisors\"}]\n27:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/about-us#careers\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"className\":\"text-white text-b3\",\"children\":\"Careers\"}]\n28:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/contact\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"className\":\"text-white text-b3\",\"children\":\"Contact\"}]\n29:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/our-approach\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"className\":\"text-white text-b3\",\"children\":\"Our Approach\"}]\n2a:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/pipeline\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"className\":\"text-white text-b3\",\"children\":\"Pipeline\"}]\n2b:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/pipeline/#indications\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"className\":\"text-white text-b3\",\"children\":\"Indications\"}]\n2c:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"hr"])</script><script>self.__next_f.push([1,"ef\":\"/publications\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"className\":\"text-white text-b3\",\"children\":\"Publications\"}]\n2d:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/pipeline/#clinical-trials\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"className\":\"text-white text-b3\",\"children\":\"Clinical Trials\"}]\n2e:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/privacy-policy\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"className\":\"text-b3 hover:underline\",\"children\":\"Privacy \u0026 Cookies Policy\"}]\n2f:[\"$\",\"$L18\",null,{\"defaultLocale\":\"en-US\",\"href\":\"/accessibility-statement\",\"locale\":\"$undefined\",\"localeCookie\":false,\"unprefixed\":\"$undefined\",\"className\":\"text-b3 hover:underline\",\"children\":\"Accessibility\"}]\n"])</script></body></html>